Abstract 145P
Background
Implementation of preoperative CRT in patients (pts) with locally advanced R-ESCC is suboptimal for many reasons, including safety concerns. PET/CT scanning has shown positive predictive data and may help optimize neoadjuvant treatment in R-ESCC. We report the primary analysis of an ongoing, phase 2, multicenter study conducted in China, which investigated the efficacy and safety of PET/CT-guided neoadjuvant treatment with TIS, an anti-programmed cell death protein 1 antibody, plus Chemo/CRT in R-ESCC (NCT04974047).
Methods
Therapy-naïve adult pts with AJCC 8th Ed. Stage cT1-2N+M0 or cT3NanyM0 R-ESCC received a PET/CT scan at baseline (BL), then one cycle of induction Chemo (cisplatin-paclitaxel [Cis-Pac]), and another PET/CT scan 15-21 days later. Pts were categorized into two cohorts per response to induction Chemo, based on the decrease from BL in PET maximum standardized uptake value in the primary tumor (responders [R]: ≥35%, nonresponders [NR]: <35%). Both cohorts received three cycles of TIS 200 mg IV + two cycles of Chemo (Cis-Pac) Q3W for R or two cycles of CRT (investigator-chosen Cis-Pac or Cis-5-FU + radiotherapy [40 Grays in 20 fractions]) for NR. Pts then underwent surgery. The primary endpoint was postresection pathological complete response (pCR) rate; secondary endpoints included R0 resection rate and safety (adverse events [AEs]).
Results
Of 70 pts enrolled, 15 (21%) and 48 (69%) had stage II and III disease at BL, respectively. Thirty pts were R and 40 were NR to induction Chemo. Of the R, 21 (70%) had undergone surgery; the pCR rate was 29% (n=6; 95% CI: 11, 52); the R0 resection rate was 95%. Of the NR, 33 (83%) had undergone surgery; the pCR rate was 33% (n=11; 95% CI: 18, 52); the R0 resection rate was 91%. Fourteen pts (47%) in the R cohort and 33 pts (83%) in the NR cohort had ≥grade 3 treatment-related AEs (TRAEs); AEs leading to treatment discontinuation occurred in one pt (3%) and four pts (10%), respectively. No pts had surgery canceled due to AEs. No TRAEs leading to death were reported.
Conclusions
As neoadjuvant treatment in pts with R-ESCC, TIS + Chemo/CRT demonstrated promising pCR rates and tolerable safety in both R and NR (PET/CT-assessed).
Clinical trial identification
NCT04974047, first posted July 23, 2021.
Editorial acknowledgement
This study was sponsored by BeiGene, Ltd. Medical writing support, under direction of the authors, was provided by Ghina Yaacoub, MSc, of Ashfield MedComms, an Inizio company, and was funded by BeiGene, Ltd.
Legal entity responsible for the study
BeiGene, Ltd.
Funding
BeiGene, Ltd.
Disclosure
L. Chen, Y. Liao, T. Jiang, M. Kang, X. Mei, L. Tan, J. Liu, H. Jiang: Non-Financial Interests, Institutional, Principal Investigator: BeiGene. Z. Zhang, W. Yu: Financial Interests, Personal, Full or part-time Employment: BeiGene. L. Li: Financial Interests, Personal, Full or part-time Employment: BeiGene (Beijing) Co., Ltd; Financial Interests, Personal, Stocks/Shares: BeiGene (Beijing) Co., Ltd; Financial Interests, Personal, Training: BeiGene (Beijing) Co., Ltd.
Resources from the same session
602P - COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (Enco) + binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mutant melanoma
Presenter: Andrew Haydon
Session: Poster Display
Resources:
Abstract
603P - An individualised postoperative radiological surveillance schedule for IDH-wildtype glioblastoma patients (HK-GBM Registry)
Presenter: Jason Chak Yan Li
Session: Poster Display
Resources:
Abstract
604P - Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who progressed after prior VEGFR-targeted therapy: Outcomes from COSMIC-311 by BRAF status
Presenter: Marcia Brose
Session: Poster Display
Resources:
Abstract
606P - BRAF and NRAS mutations are associated with poor prognosis in Asians with acral-lentiginous and nodular cutaneous melanoma
Presenter: Sumadi Lukman Anwar
Session: Poster Display
Resources:
Abstract
607P - Single institutional outcomes of radiotherapy and systemic therapy for melanoma brain metastases in Japan
Presenter: Naoya Yamazaki
Session: Poster Display
Resources:
Abstract
608P - The efficacy of immune checkpoint inhibitors and targeted therapy in mucosal melanomas: A systematic review and meta-analysis
Presenter: Andrea Teo
Session: Poster Display
Resources:
Abstract
609P - The association between thyroid function abnormalities and vitiligo induced by pembrolizumab regarding prognosis in patients with advanced melanoma
Presenter: Moez Mobarek
Session: Poster Display
Resources:
Abstract
610P - Analyzing the clinical benefit of the evidence presented at these congresses and utilizing a standardized scale to quantify it will significantly enhance our understanding of the studies showcased, allowing for more objective evaluation and interpretation
Presenter: Charles Jeffrey Tan
Session: Poster Display
Resources:
Abstract
611P - ESMO-magnitude of clinical benefit scale (MCBS) scores for phase III trials of adjuvant and curative therapies at the 2022 ASCO annual meeting (ASCO22)
Presenter: Thi Thao Vi Luong
Session: Poster Display
Resources:
Abstract
612P - Is the juice worth the squeeze? Overall survival gain per unit treatment time as a metric of clinical benefit of systemic treatment in incurable cancers
Presenter: Vodathi Bamunuarachchi
Session: Poster Display
Resources:
Abstract